Johnson & Johnson
JNJ
$271.19
+2.01%
Johnson & Johnson is the world's largest and most diversified healthcare company, operating through two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Following the divestiture of its consumer health business (Kenvue) in 2023, the company has sharpened its focus on high-growth areas like oncology, immunology, and neurology, while maintaining a leadership position in medical devices. The current investor narrative centers on the company's robust pipeline, recent FDA clearance for its surgical robot, and a proposed talc settlement that removes a major legal overhang, alongside a 64th consecutive annual dividend increase and ambitious $100 billion revenue target. The stock has rallied strongly over the past year, driven by solid earnings, raised guidance, and optimism about new product launches, though valuation concerns are emerging.…
JNJ
Johnson & Johnson
$271.19
Related headlines
Investment Opinion: Should I buy JNJ Today?
Based on the analysis, JNJ is rated a Buy. The company's strong fundamentals, including 9.91% revenue growth, high margins, and a robust pipeline, support a positive outlook. The average analyst target of $272.50 implies a modest upside of 1.7% from the current price of $268.04, but the long-term growth potential justifies the premium.
Sign up to view all
JNJ 12-Month Price Forecast
The AI assessment is bullish on JNJ, driven by strong fundamentals and positive catalysts. However, the elevated valuation and potential risks warrant a medium confidence level. The stock's growth trajectory, pipeline, and legal resolution support a positive outlook, but any negative surprises could lead to a downgrade. Key factors to monitor include revenue growth sustainability, pipeline execution, and legal outcomes.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $272.50 and implied upside of +0.5% versus the current price.
Average Target
$272.50
0 analysts
Implied Upside
+0.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$190 - $305
Analyst target range
The wide range between the low and high targets ($190 to $305) indicates high uncertainty about the company's future prospects, which is typical for a large-cap healthcare company facing patent expirations and legal challenges. The high target assumes successful execution of the pipeline and continued growth in MedTech, while the low target prices in potential setbacks. Recent institutional ratings show a mix of 'Buy', 'Overweight', and 'Neutral' actions, with no major downgrades, suggesting that sentiment remains positive but cautious. The narrow spread between the current price and the average target suggests that the stock is fairly valued, and investors should look for catalysts to drive further upside.
Drowning in data?
Find the real signal!
Bulls vs Bears: JNJ Investment Factors
Johnson & Johnson presents a compelling bull case with accelerating revenue growth, a strong pipeline, and the removal of a major legal overhang. However, the stock's elevated valuation and potential patent cliffs introduce significant bear risks. Currently, the bull case has stronger evidence, supported by robust fundamentals and positive catalysts, but the valuation leaves little room for error. The key tension is whether the company can sustain its growth momentum to justify the premium multiple, or if patent expirations and competitive pressures will lead to a de-rating.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 9.91% YoY to $24.06B, up from ~2% growth in prior quarters, driven by Innovative Medicine and MedTech. This acceleration supports the company's $100B revenue target and indicates strong commercial execution.
- High Gross Margin and Profitability: Gross margin stands at 71.49% in Q1 2026, with operating margin at 26.58% and net margin at 21.76%. These metrics reflect strong pricing power and operational efficiency, underpinning robust cash generation.
- Legal Overhang Removal via Talc Settlement: The proposed talc settlement removes a major litigation overhang, reducing uncertainty and potential liabilities. This has been a key driver of the stock's recent rally and improves the risk profile for investors.
- Strong Pipeline and New Product Launches: FDA clearance for the surgical robot and a robust drug pipeline in oncology, immunology, and neurology provide multiple growth catalysts. These innovations are expected to drive revenue growth and market share gains.
Bearish
- Elevated Valuation vs. Historical Norms: The stock trades at a forward PE of 21.78x, above its 5-year average of ~16x. The current price is near the 52-week high, leaving limited margin of safety and increasing vulnerability to earnings disappointments.
- Patent Expirations and Biosimilar Competition: Key drugs like Stelara face patent cliffs, and biosimilar competition could erode revenue. The company's reliance on a few blockbusters for growth creates concentration risk.
- Talc Litigation Uncertainty Persists: Despite the proposed settlement, legal challenges remain, and the final approval is not guaranteed. Adverse court rulings could result in higher costs and reputational damage.
- High R&D Spending with Uncertain Returns: R&D expenses were $3.53B in Q1 2026, up significantly YoY. While necessary for growth, the high spending increases pressure to deliver successful pipeline outcomes, and failures could weigh on sentiment.
JNJ Technical Analysis
Johnson & Johnson's stock is in a strong uptrend, with a 1-year price change of +52.77%, significantly outperforming the S&P 500's +18.56% over the same period. The current price of $268.04 is near the top of its 52-week range, sitting at approximately 97% of the range (calculated as (268.04 - 173.33) / (276.47 - 173.33) = 0.97), indicating strong momentum and bullish sentiment. This positioning near the highs suggests the market is rewarding the company's execution, but also raises the risk of overextension, as the stock may be pricing in optimistic expectations.
Beta
0.23
0.23x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$173-$276
Price range past year
Annual Return
+53.1%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | +5.8% | +2.0% |
| 3m | +21.5% | +1.0% |
| 6m | +13.2% | +11.8% |
| 1y | +53.1% | +18.1% |
| ytd | +30.8% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Johnson & Johnson's revenue growth is accelerating, with Q1 2026 revenue of $24.06 billion, up 9.91% year-over-year, compared to a more modest growth rate in prior quarters. The company's Innovative Medicine segment generated $15.43 billion in revenue, while MedTech contributed $8.64 billion, with the former driving growth. This acceleration is supported by strong demand for oncology and immunology drugs, as well as new product launches. The company's gross margin remains high at 71.49% in Q1 2026, reflecting its pricing power and efficient cost structure, though it has slightly declined from 72.78% in the prior year.
Quarterly Revenue
$24.1B
2026-03
Revenue YoY Growth
+9.9%
YoY Comparison
Gross Margin
71.5%
Latest Quarter
Free Cash Flow
$17.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Given that Johnson & Johnson has positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE is 18.82x, while the forward PE is 21.78x, indicating that the market expects earnings growth to continue. The gap between trailing and forward PE suggests that analysts anticipate higher future earnings, which is consistent with the company's growth trajectory. However, the forward PE is higher than the trailing, which could imply that the market is pricing in a slowdown or that the current earnings are temporarily elevated due to one-time gains.
PE
18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks include a debt-to-equity ratio of 0.59, which is manageable but not negligible, and a current ratio of 1.03, indicating tight liquidity. The company's high payout ratio of 46.19% limits financial flexibility, and its reliance on continued growth to justify the valuation is a concern. Revenue concentration in the Innovative Medicine segment (64% of total) exposes the company to drug-specific setbacks, and the recent acceleration in growth may not be sustainable as patent expirations loom.
FAQ
Key risks include patent expirations on major drugs, potential legal liabilities from talc litigation, and regulatory changes in healthcare. Additionally, the stock's high valuation could lead to a de-rating if growth disappoints. The company's high payout ratio limits financial flexibility, and its reliance on a few products creates concentration risk.
The 12-month forecast is positive, with a base case target of $260-$280, reflecting the average analyst target of $272.50. The bull case targets $280-$305, while the bear case could see $190-$230. The most likely scenario is the base case, assuming continued growth and successful pipeline execution.
JNJ is trading at a forward PE of 21.78x, which is above its historical average of ~16x, indicating a premium valuation. This premium is justified by the company's growth acceleration and pipeline, but it leaves little room for error. The stock is fairly valued relative to its growth prospects, but not undervalued.
JNJ is a good buy for investors with a long-term horizon, given its strong fundamentals, pipeline, and dividend. The stock offers a modest upside to the average analyst target of $272.50, but the risk-reward is balanced. However, the elevated valuation suggests that investors should consider waiting for a pullback to improve their margin of safety.
JNJ is better suited for long-term investment, given its stable business model, dividend growth, and pipeline potential. The stock's beta of 0.23 indicates low volatility, making it a defensive holding. Short-term traders may find limited upside due to the stock's proximity to its 52-week high, but long-term investors can benefit from compounding returns and income.
